Pošlji prijatelju
RSS
google +
Različica za tiskanje

Novica (Redke bolezni)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

First treatment recommended for rare bone disease    europa.eu

Enzyme replacement therapy Strensiq to benefit patients with hypophosphatasia developed in childhood[...]

First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU    europa.eu

Farydak shown to slow progression of rare blood cancer[...]

Adamas receives Orphan drug designation for ADS-5102 for treatment of levodopa-induced dyskinesia associated with Parkinson's    epda.eu.com

Adamas Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Pa[...]

First medicine for rare blood cancer    europa.eu

EMA recommends Imbruvica for the treatment of Waldenstrӧm's macroglobulinaemia[...]

EMA recommends treatment for rare cancer in children    europa.eu

Unituxin to prolong survival in young patients with high-risk neuroblastoma[...]

Adamas receives Orphan drug designation for ADS-5102 for treatment of levodopa-induced dyskinesia associated with Parkinson's    epda.eu.com

Adamas Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Pa[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.